Statins, Lp(a), and upcoming podcast guests
In other words, statins are not addressing the associated risk in patients with an elevated Lp(a), and this population represents about 25% of those with previous CVD or an indication for statins.
#07 – Deep Dive: Lp(a) — what every doctor, and the 10-20% of the population at risk, needs to know
“Elevated Lp(a) may have conferred a survival advantage for most of human history: a better ability to deal with acute trauma, but possibly at the expense of poor handling of chronic damage. In today’s environment, for many people, that’s not an advantage.” —Peter Attia
#03 – Ron Krauss, M.D.: a deep dive into heart disease
“Anybody interested in this field should probably understand the origins.” —Ron Krauss
Podcast, AMA, Lp(a), and Dr. Rosenrosen
Bob Kaplan, my head analyst, had the opportunity to drink all of my espresso while he “asked me anything.”
A big predictor of heart disease risk that most doctors don’t screen for
The most interesting article I read this week was this paper on the NHLBI’s recommendations to reduce Lp(a)-mediated risk of cardiovascular disease.
How did we come to believe saturated fat and cholesterol are bad for us?
There aren’t too many topics that really get me riled up anymore. I’m too old and too busy to care…
The straight dope on cholesterol – Part IX
In this post we’ll address the following concept: What should you eat to have the greatest chance of delaying the arrival of cardiovascular disease?
The straight dope on cholesterol – Part VIII
In this post we’ll double-click on a paper covering cholesterol and heart disease risk factors.
The straight dope on cholesterol – Part VII
In this post we’ll address the following concept: Does “HDL” matter after all?
The straight dope on cholesterol – Part VI
In this post we’ll address the following concept: Why is it necessary to measure LDL-P, instead of just LDL-C?